AMGN vs REGN vs ARGX Stock Comparison

Amgen, Regeneron Pharmaceuticals and Argenx Se Prices as of Nov 13, 2026 Peers: Industry group
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$253.29B
P/E
27.0x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
4 wins
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$59.19B
P/E
31.5x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins

Head to Head

11 decided of 12

Amgen leads on 4 of the 12 questions below (Amgen 4, Argenx Se 4, Regeneron Pharmaceuticals 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMGNREGNARGXLeader
Larger companyMarket capitalisation $253.29B $97.63B $59.19B AMGN
Cheaper on earningsLower P/E, profitable companies only 27.0x 20.3x 31.5x REGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 20.9x 14.8x 32.8x REGN
Faster revenue growthRevenue growth, trailing twelve months +8.2% +18.6% +61.5% ARGX
More profitableNet margin, trailing twelve months 24.1% 28.5% 32.3% ARGX
Better return on capitalReturn on invested capital 15.6% 11.9% — AMGN
Less leveragedLower net debt / EBITDA 2.4x -1.4x — REGN
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +38.6% +37.5% +7.7% AMGN
Better 5-year returnAnnualised price return, 5 years +17.1%/yr +8.7%/yr +25.4%/yr ARGX
Less volatileAnnualised volatility, 1 year 28.8% 33.9% 37.7% AMGN
Higher overall scoreMean of the five percentile scores vs peers 66/100 73/100 92/100 ARGX

Percentile Scorecard

AMGNREGNARGX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGNREGNARGX
Valuation 85 #103 of 660 89 #75 of 660 82 #122 of 660
Growth 61 #245 of 619 50 #308 of 619 96 #27 of 619
Profitability 95 #32 of 595 92 #48 of 595 99 #9 of 595
Financial Health 23 #528 of 683 71 #199 of 683 –
Shareholder Returns 67 #152 of 459 63 #170 of 459 –
Overall 66 73 92
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • REGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNREGNARGXSPY
1 month +9.3%+22.8%+17.3% -2.0%
3 months +12.2%+18.9%+12.8% -2.8%
6 months +42.7%+36.8%+20.1% +2.0%
Year to date +42.3%+23.8%+14.2% +10.6%
1 year +38.6%+37.5%+7.7% +12.2%
3 years +72.5%+20.4%+96.0% +68.1%
3 years, per year +19.9%+6.4%+25.2% +18.9%
5 years +120.3%+51.4%+210.1% +61.4%
5 years, per year +17.1%+8.7%+25.4% +10.1%
10 years +212.4%+127.6%— +248.5%
10 years, per year +12.1%+8.6%— +13.3%

Risk

MeasureAMGNREGNARGXSPY
Volatility, 1Y 28.8%33.9%37.7% 13.6%
Downside volatility, 1Y 28.4%30.8%35.2% 13.9%
Beta vs S&P 500, 1Y 0.490.350.54 1.00
Return / volatility, 1Y 1.341.110.20 0.90
Max drawdown, 5Y -26.7%-59.8%-38.2% -25.4%
From 52-week high -2.7%-1.8%-9.3% -3.2%
52-week high $478.48$973.36$1,058.90 $779.14
52-week low $313.85$600.66$663.93 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGNREGNARGX
P/E now vs peer median 26.8xmedian 17.0x 20.2xmedian 17.0x 31.4xmedian 17.0x
P/S now vs peer median 6.5xmedian 8.4x 5.8xmedian 8.4x 10.2xmedian 8.4x
EV/EBITDA now vs peer median 17.1xmedian 14.6x 16.7xmedian 14.6x —median 14.6x
P/FCF now vs peer median 26.3xmedian 19.0x 25.4xmedian 19.0x —median 19.0x
P/B now vs peer median 17.6xmedian 2.0x 2.9xmedian 2.0x —median 2.0x
PEG now vs peer median 3.86median 0.43 2.23median 0.43 0.30median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGNREGNARGX
Revenue $38.90B $16.90B $5.82B
Gross profit $27.58B $14.49B $5.24B
Operating income $12.61B $4.86B $1.74B
Net income $9.39B $4.82B $1.88B
Free cash flow $9.58B $3.83B –
R&D $7.84B $6.60B $1.80B
EPS (diluted) $17.20 $45.62 $28.43
Cash & equivalents $13.19B $3.66B –
Total debt $54.01B $1.99B –
Shares (diluted) 546.00M 105.60M 66.03M
Enterprise value $204.94B $62.97B $59.19B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGNREGNARGX
P/E 26.8x 20.2x 31.4x
P/FCF 26.3x 25.4x –
P/Operating cash flow 20.9x 20.1x –
P/S 6.5x 5.8x 10.2x
P/B 17.6x 2.9x –
P/Tangible book -48.6x 3.0x –
EV/EBITDA 17.1x 16.7x –
EV/EBIT 23.2x 18.5x 34.1x
EV/Revenue 7.5x 5.3x 10.2x
EV/FCF 30.5x 23.5x –
EV/Operating cash flow 24.3x 18.5x –
PEG (3Y EPS CAGR) 3.86 2.23 0.30

Growth

14 metrics
MetricAMGNREGNARGX
Revenue growth (1Y) 8.2% 18.6% 61.5%
Revenue CAGR (3Y) 13.2% 8.9% 80.5%
Gross profit growth (1Y) 15.9% 19.1% 62.2%
Gross profit CAGR (3Y) 11.8% 8.8% 80.0%
Operating income growth (1Y) 45.4% 31.9% 120.6%
Operating income CAGR (3Y) 12.5% 4.8% 85.1%
Net income growth (1Y) 34.1% 5.2% 22.5%
Net income CAGR (3Y) 7.5% 6.5% 115.5%
EPS growth (1Y) 33.1% 6.8% 20.9%
EPS CAGR (3Y) 6.9% 9.0% 104.8%
Operating cash flow growth (1Y) -8.3% -4.4% –
Operating cash flow CAGR (3Y) 4.4% -2.5% –
Free cash flow growth (1Y) -17.0% -9.4% –
Free cash flow CAGR (3Y) 0.7% -6.0% –

Profitability

14 metrics
MetricAMGNREGNARGX
Gross margin 70.9% 85.8% 90.0%
EBITDA margin 43.9% 31.8% –
Operating margin 32.4% 28.8% 29.9%
Pretax margin 28.4% 33.7% 32.6%
Net margin 24.1% 28.5% 32.3%
FCF margin 24.6% 22.6% –
Operating cash flow margin 30.9% 28.7% –
Return on equity 72.1% 14.0% –
Return on assets 9.8% 10.6% –
Return on invested capital 15.6% 11.9% –
Return on capital employed 17.4% 13.2% –
Asset turnover 0.4x 0.4x –
Cash conversion (OCF / net income) 1.3x 1.0x –
Stock comp / revenue 1.3% 6.0% –

Financial Health

11 metrics
MetricAMGNREGNARGX
Debt / assets 56.2% 4.5% –
Debt / equity 3.8x 0.1x –
Net debt / EBITDA 2.4x -1.4x –
Debt / FCF 5.6x 0.5x –
Liabilities / assets 85.1% 24.6% –
Equity / assets 14.9% 75.4% –
Interest coverage 4.8x 104.2x 10,120x
Current ratio 1.5x 3.4x –
Quick ratio 1.0x 2.7x –
Cash ratio 0.6x 1.5x –
Altman Z-score 2.54 7.73 –

Shareholder Returns

7 metrics
MetricAMGNREGNARGX
Dividend yield 2.1% 0.4% –
Net buyback yield – 2.1% –
Shareholder yield 2.1% 2.5% –
Payout ratio (earnings) 57.1% – –
Payout ratio (FCF) 56.0% – –
Dividend growth (1Y) 6.3% – –
Dividend CAGR (3Y) 6.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGNREGNARGX
Forward P/E 20.9xFY2026 14.8xFY2026 32.8xFY2026
EPS, next fiscal year $22.28FY2026 $64.62FY2026 $29.27FY2026
EPS growth, next FY +2.0%FY2026 +45.8%FY2026 +49.6%FY2026
EPS growth, the year after +7.2% +13.6% +32.0%
Revenue, next fiscal year $42.01BFY2026 $18.08BFY2026 $6.16BFY2026
Revenue growth, next FY +14.3%FY2026 +26.1%FY2026 +44.9%FY2026
Revenue growth, the year after +3.1% +14.6% +24.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGNREGNARGX
Held by institutions 82.7% 66.2% 46.1%
Institutions holding 3,163 1,329 506
Change in shares held, QoQ +4.5% +3.8% -2.0%
Institutions buying 1,452 607 263
Institutions selling 1,219 534 162
Buyers to sellers 1.19 1.14 1.62

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMGNREGNARGX
AMGN 1.00 0.46 0.33
REGN 0.46 1.00 0.20
ARGX 0.33 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMGN, REGN and ARGX?

Amgen (AMGN) is the largest by market capitalisation: Amgen (AMGN) $253.29B, Regeneron Pharmaceuticals (REGN) $97.63B, Argenx Se (ARGX) $59.19B.

Which stock is cheaper, AMGN, REGN and ARGX?

Regeneron Pharmaceuticals (REGN) trades on the lowest price-to-earnings ratio (Amgen (AMGN) 27.0x, Regeneron Pharmaceuticals (REGN) 20.3x, Argenx Se (ARGX) 31.5x). On next year's consensus earnings, Regeneron Pharmaceuticals (REGN) is cheapest (Amgen (AMGN) 20.9x, Regeneron Pharmaceuticals (REGN) 14.8x, Argenx Se (ARGX) 32.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Argenx Se (ARGX) grew revenue fastest over the trailing twelve months: Amgen (AMGN) +8.2%, Regeneron Pharmaceuticals (REGN) +18.6%, Argenx Se (ARGX) +61.5%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Amgen (AMGN) 24.1%, Regeneron Pharmaceuticals (REGN) 28.5%, Argenx Se (ARGX) 32.3%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 15.6%, Regeneron Pharmaceuticals (REGN) 11.9%).

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Amgen (AMGN) +38.6%, Regeneron Pharmaceuticals (REGN) +37.5%, Argenx Se (ARGX) +7.7%. Over five years, Argenx Se (ARGX) compounded fastest (Amgen (AMGN) +17.1%/yr, Regeneron Pharmaceuticals (REGN) +8.7%/yr, Argenx Se (ARGX) +25.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%, Regeneron Pharmaceuticals (REGN) 0.00%, Argenx Se (ARGX) 0.00%. Regeneron Pharmaceuticals (REGN) and Argenx Se (ARGX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Amgen (AMGN) 28.8%, Regeneron Pharmaceuticals (REGN) 33.9%, Argenx Se (ARGX) 37.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMGN, REGN and ARGX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.